COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: In the intervention group, participants will receive new trial drug 6 drops every 3hours for 14 days. The control group will receive a placebo (no therapeutic value), resembled the
Sponsors
Health Medicine Chemistry Company
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: Having definite COVID-19 disease and get hospitalized Both sexes Age over 15 years Obtaining informed consent to participate in the trial Non-participation in another clinical trial simultaneously Patients admitted to ICU
Exclusion criteria
Exclusion criteria: Diagnosis of the disease just based on physician diagnosis Pregnancy (according to the patient's statement and examination by a physician) Breastfeeding (according to the patient's statement)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White Blood Cell count. Timepoint: Before intervention and 14 days after intervention. Method of measurement: Laboratory cell counter.;Serum CRP level. Timepoint: Before intervention and 14 days after intervention. Method of measurement: Biochemical method.;ESR (Erythrocyte Sedimentation Rate). Timepoint: Before intervention and 14 days after intervention. Method of measurement: Checking the sedimentation rate of erythrocytes in a special tube within one hour.;Number of hospitalization days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The end time of dry Cough. Timepoint: Daily. Method of measurement: ?Daily symptom recording questionnaire.;The time of recovery from difficulty in breathing or shortness of breath. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;The time of recovery of temperature equal to or grater than 37.8 C. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Hosseinpour
Health Medicine Chemistry Company
Outcome results
None listed